Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20684195 | 0.83 | RORC (0.48) | RORCIL17A | |
| SCHEMBL17843388 | 0.81 | MCL1 (0.52) | RORCIL17A | |
| SCHEMBL15981011 | 0.81 | RORC (0.53) | RORC | |
| SCHEMBL14831323 | 0.81 | MCL1 (0.57) | RORC | |
| SCHEMBL17843299 | 0.81 | RORC (0.63) | RORCIL17A | |
| SCHEMBL20280650 | 0.81 | RORC (0.63) | RORCIL17A | |
| SCHEMBL28503119 | 0.80 | RORC (0.52) | RORCIL17A | |
| SCHEMBL17843349 | 0.80 | RORC (0.55) | RORCIL17A | |
| SCHEMBL14831320 | 0.79 | RORC (0.56) | RORCIL17A | |
| SCHEMBL17858289 | 0.77 | RORC (0.52) | RORCIL17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107257788-B | Benzenesulfonamide derivatives as inverse agonists of the retinoid-related orphan receptor gamma (ROR gamma (t)) | 盖尔德马研究及发展公司 | 2020-11-10 | — | — | CN | disclosed |
| US-10457637-B2 | Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-10-29 | — | — | US | disclosed |
| US-10457637-B2 | Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-10-29 | — | — | US | disclosed |
| EP-3233848-B1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | disclosed |
| EP-3233848-B1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RES & DEV (FR) | 2019-01-30 | — | — | EP | disclosed |
| US-20180170869-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-06-21 | — | — | US | disclosed |
| US-20180170869-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-06-21 | — | — | US | disclosed |
| EP-3233848-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | Galderma Research & Development (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097389-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170869-A1 | BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORB, RORA, RORC | RORC 3/4885IL17A 180/4885 |
| US-10457637-B2 | Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) | RORB, RORA, RORC | RORC 3/4885IL17A 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.